Tempus AI

TEMPhase 2

Tempus AI operates at the intersection of healthcare and artificial intelligence, providing precision medicine solutions through its comprehensive genomic and clinical data platform. The company serves oncology and other therapeutic areas by offering diagnostic testing, real-world data analytics, and AI-driven insights to improve patient outcomes. As a publicly traded company, Tempus has established itself as a key player in the precision medicine ecosystem.

Market Cap

$8.2B

Employees

1,000-2,000

Focus

Biotech

TEM · Stock Price

USD 46.96+6.71 (+16.67%)

Historical price data

AI Company Overview

Technology Platform

AI-powered precision medicine platform that combines genomic sequencing, clinical data analytics, and machine learning to provide diagnostic testing and real-world evidence solutions for healthcare providers and pharmaceutical companies.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
Pegylated IFN- alpha 2b + Ribavirin	Hepatitis C	Approved
Pegylated interferon alpha 2 + Ribavirin	Hepatitis C	Approved
Targeted Therapy Based on Molecular Profiling + Standard-of-Care Therapy	Metastatic Malignant Neoplasm	Phase 2
Niraparib	Solid Tumor	Phase 2
A2B694 + A2B543	Solid Tumor, Adult	Phase 1/2

Opportunities

Significant growth opportunities in expanding precision medicine adoption, international market penetration, and leveraging AI capabilities for drug discovery partnerships.

The company is well-positioned to benefit from increasing healthcare digitization and personalized medicine trends.

Risk Factors

Key risks include intense competition in the AI healthcare space, regulatory challenges around AI-powered diagnostics, and the need to continuously demonstrate clinical utility and economic value of precision medicine approaches to drive adoption.

Competitive Landscape

Competes with established players like Foundation Medicine, Guardant Health, and Illumina, while differentiating through its comprehensive AI-powered data platform and integrated approach to precision medicine across the healthcare value chain.

Publications

Patents

Pipeline